Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Testing Cooperative's Hematologic Neoplasms, Solid Tumor Tests Receive NY State Approval, Medicare Coverage

NEW YORK – Genomic Testing Cooperative announced on Wednesday that the New York State Clinical Evaluation Program has approved its next-generation sequencing profiling tests for hematologic neoplasms and solid tumors.

The approved tests are the GTC Hematology Profile for 177 genes; GTC Hematology Fusion/Expression for 1,408 genes; GTC Hematology PLUS for 177 DNA and 1,408 RNA; GTC Liquid Biopsy, Hematology Profile for 177 genes; GTC Solid Tumor Profile for 434 genes; GTC Solid Tumor Profile Fusion/Expression for 1,408 genes; and GTC Solid Tumor PLUS for 434 DNA and 1,408 RNA.

The tests are also covered by Medicare Administrative Contractor Palmetto GBA, Irvine, California-based GTC said in a statement, adding they are designed to comprehensively evaluate "clinically relevant molecular abnormalities and biomarkers." The tests can be performed on small samples, including needle aspiration samples, and rely on artificial intelligence to analyze sequencing runs, curate data, and interpret results.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.